Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion

References

• Papakostas GI, Nutt DJ, Hallett LA et al. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biol. Psychiatry60(12), 1350–1355 (2006).
   PubMed Web of Science ®Google Scholar
• Burks TF. New agents for the treatment of cancer-related fatigue. Cancer92(Suppl. 6), 1714–1718 (2001).
   PubMedGoogle Scholar
• Vassout A, Bruinink A, Krauss J et al. Regulation of dopamine receptors by bupropion: comparison with antidepressants and CNS stimulants. J. Recept. Res.13(1–4), 341–354 (1993).
   PubMed Web of Science ®Google Scholar
• Hoffman DC. The use of place conditioning in studying the neuropharmacology of drug reinforcement. Brain Res. Bull.23(4–5), 373–387 (1989).
   PubMedGoogle Scholar
• Davis JM, Alderson NL, Welsh RS. Serotonin and central nervous system fatigue: nutritional considerations. Am. J. Clin. Nutr.72(Suppl. 2), 573S–578S (2000).
   PubMed Web of Science ®Google Scholar
• Stahl SM, Zhang L, Damatarca C et al. Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J. Clin. Psychiatry64(Suppl. 14), 6–17 (2003).
   Google Scholar
• David A, Pelosi A, McDonald E et al. Tired, weak, or in need of rest: fatigue among general practice attenders. Br. Med. J.301(6762), 1199–1202 (1990).
   PubMed Web of Science ®Google Scholar
• Walker EA, Katon WJ, Jemelka RP. Psychiatric disorders and medical care utilization among people in the general population who report fatigue. J. Gen. Intern. Med.8(8), 436–440 (1993).
   PubMed Web of Science ®Google Scholar
• Pawlikowska T, Chalder T, Hirsch SR et al. Population based study of fatigue and psychological distress. Br. Med. J.308(6931), 763–766 (1994).
   PubMed Web of Science ®Google Scholar
• Kroenke K, Price RK. Symptoms in the community. Prevalence, classification, and psychiatric comorbidity. Arch. Intern. Med.153(21), 2474–2480 (1993).
   PubMed Web of Science ®Google Scholar
• Maurice-Tison S, Verdoux H, Gay B et al. How to improve recognition and diagnosis of depressive syndromes using international diagnostic criteria. Br. J. Gen. Pract.48(430), 1245–1246 (1998).
   PubMed Web of Science ®Google Scholar
• Tylee A, Gastpar M, Line JP et al. DEPRES II (Depression Research in European Society II), a patient survey of the symptoms, disability and current management of depression in the community. DEPRES steering committee. Int. Clin. Psychopharmacol.14(3), 139–151 (1999).
   PubMed Web of Science ®Google Scholar
• Addington AM, Gallo JJ, Ford DE et al. Epidemiology of unexplained fatigue and major depression in the community: the Baltimore ECA follow-up, 1981–1994. Psychol. Med.31(6), 1037–1044 (2001).
   PubMed Web of Science ®Google Scholar
• Hickie I, Davenport T, Issakidis C et al. Neurasthenia: prevalence, disability and health care characteristics in the Australian community. Br. J. Psychiatry181, 56–61 (2002).
   PubMed Web of Science ®Google Scholar
• Cathebras PJ, Robbins JM, Kirmayer LJ et al. Fatigue in primary care: prevalence, psychiatric comorbidity, illness behavior, and outcome. J. Gen. Intern. Med.7(3), 276–286 (1992).
   PubMed Web of Science ®Google Scholar
• Ridsdale L, Evans A, Jerrett W et al. Patients with fatigue in general practice: a prospective study. Br. Med. J.307(6896), 103–106 (1993).
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Itri LM. Cancer-related fatigue: guidelines for evaluation and management. Oncologist4(1), 1–10 (1999).
   PubMedGoogle Scholar
• Schwartz JE, Jandorf L, Krupp LB. The measurement of fatigue: a new instrument. J. Psychosom. Res.37(7), 753–762 (1993).
   PubMed Web of Science ®Google Scholar
• Mendoza TR, Wang XS, Cleeland CS et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer85(5), 1186–1196 (1999).
   PubMed Web of Science ®Google Scholar
• Lane TJ, Matthews DA, Manu P. The low yield of physical examinations and laboratory investigations of patients with chronic fatigue. Am. J. Med. Sci.299(5), 313–318 (1990).
   PubMed Web of Science ®Google Scholar
• Sugarman JR, Berg AO. Evaluation of fatigue in a family practice. J. Fam. Pract.19(5), 643–647 (1984).
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders – Fourth Edition. American Psychiatric Association, VA, USA (1994).
   Google Scholar
• World Health Organization. The International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10). American Psychiatric Publishing, Inc., VA, USA (1992).
   Google Scholar
• Demyttenaere K, De Fruyt JG, Stahl SM. The many faces of fatigue in major depressive disorder. Int. J. Neuropsychopharmacol.8(1), 93–105 (2005).
   PubMed Web of Science ®Google Scholar
• Christensen L, Duncan K. Distinguishing depressed from nondepressed individuals using energy and psychosocial variables. J. Consult. Clin. Psychol.63(3), 495–498 (1995).
   PubMedGoogle Scholar
• Hamilton M. Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol.6(4), 278–296 (1967).
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry134, 382–389 (1979).
   PubMed Web of Science ®Google Scholar
• Beck A, Steer R, Brown G. Manual for Beck Depression Inventory II (BDI-II). Psychology Corporation, San Antonio, TX, USA (1996).
   Google Scholar
• Gullion CM, Rush AJ. Toward a generalizable model of symptoms in major depressive disorder. Biol. Psychiatry44(10), 959–972 (1998).
   PubMedGoogle Scholar
• Fehnel SE, Bann CM, Hogue SL et al. The development and psychometric evaluation of the Motivation and Energy Inventory (MEI). Qual. Life Res.13(7), 1321–1336 (2004).
   PubMed Web of Science ®Google Scholar
• Jefferson JW, Rush AJ, Nelson JC et al. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest. Findings from a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry67(6), 865–873 (2006).
   PubMed Web of Science ®Google Scholar
• Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and Multiple Sclerosis. Paralysed Veterans of America. Demos Medical Publishing, NY, USA (1998).
   Google Scholar
• Kos D, Kerckhofs E, Nagels G, et al. Origin of fatigue in multiple sclerosis: review of the literature. Neurorehabil. Neural Repair (2007) (Epub ahead of print).
   PubMedGoogle Scholar
• Nierenberg AA, Keefe BR, Leslie VC et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J. Clin. Psychiatry60(4), 221–225 (1999).
   PubMed Web of Science ®Google Scholar
• Skapinakis P, Lewis G, Mavreas V. Temporal relations between unexplained fatigue and depression: longitudinal data from an international study in primary care. Psychosom. Med.66(3), 330–335 (2004).
   PubMed Web of Science ®Google Scholar
• Moos RH, Cronkite RC. Symptom-based predictors of a 10-year chronic course of treated depression. J. Nerv. Ment. Dis.187(6), 360–368 (1999).
   PubMed Web of Science ®Google Scholar
• Staub F, Bogousslavsky J. Fatigue after stroke: a major but neglected issue. Cerebrovasc. Dis.12(2), 75–81 (2001).
   PubMed Web of Science ®Google Scholar
• Glader EL, Stegmayr B, Asplund K. Poststroke fatigue: a 2-year follow-up study of stroke patients in Sweden. Stroke33(5), 1327–1333 (2002).
   PubMed Web of Science ®Google Scholar
• Chau DT, Roth RM, Green AI. The neural circuitry of reward and its relevance to psychiatric disorders. Curr. Psychiatry Rep.6(5), 391–399 (2004).
   PubMedGoogle Scholar
• Salamone JD, Correa M, Mingote S, Weber SM. Nucleus accumbens dopamine and the regulation of effort in food-seeking behavior: implications for studies of natural motivation, psychiatry, and drug abuse. J. Pharmacol. Exp. Ther.305(1), 1–8 (2003).
   PubMed Web of Science ®Google Scholar
• Lorist MM, Boksem MA, Ridderinkhof KR. Impaired cognitive control and reduced cingulate activity during mental fatigue. Brain research. Brain Res. Cogn. Brain Res.24(2), 199–205 (2005).
   PubMedGoogle Scholar
• Okada T, Tanaka M, Kuratsune H, et al. Mechanisms underlying fatigue: a voxel-based morphometric study of chronic fatigue syndrome. BMC Neurol.4(1), 14 (2004).
   PubMedGoogle Scholar
• Krupp LB, Pollina DA. Mechanisms and management of fatigue in progressive neurological disorders. Curr. Opin. Neurol.9(6), 456–460 (1996).
   PubMed Web of Science ®Google Scholar
• Demitrack MA, Gold PW, Dale JK et al. Plasma and cerebrospinal fluid monoamine metabolism in patients with chronic fatigue syndrome: preliminary findings. Biol. Psychiatry32(12), 1065–1077 (1992).
   PubMed Web of Science ®Google Scholar
• Verhoeff NP, Christensen BK, Hussey D et al. Effects of catecholamine depletion on D2 receptor binding, mood, and attentiveness in humans: a replication study. Pharmacol. Biochem. Behav.74(2), 425–432 (2003).
   PubMed Web of Science ®Google Scholar
• Katz MM, Tekell JL, Bowden CL et al. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology29(3), 566–579 (2004).
   PubMed Web of Science ®Google Scholar
• Dubini A, Bosc M, Polin V. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. J. Psychopharmacol. (Oxford)11(Suppl. 4), S17–S23 (1997).
   Web of Science ®Google Scholar
• Schroeder DH. Metabolism and kinetics of bupropion. J. Clin. Psychiatry44(5 Pt 2), 79–81 (1983).
   PubMed Web of Science ®Google Scholar
• Hsyu PH, Singh A, Giargiari TD et al. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J. Clin. Pharmacol.37(8), 737–743 (1997).
   PubMed Web of Science ®Google Scholar
• Holm KJ, Spencer CM. Bupropion: a review of its use in the management of smoking cessation. Drugs59(4), 1007–1024 (2000).
   PubMed Web of Science ®Google Scholar
• Findlay JW, Van Wyck Fleet J, Smith PG et al. Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Eur. J. Clin. Pharmacol.21(2), 127–135 (1981).
   PubMed Web of Science ®Google Scholar
• Foley KF, DeSanty KP, Kast RE. Bupropion: pharmacology and therapeutic applications. Expert Rev. Neurother.6(9), 1249–1265 (2006).
   PubMed Web of Science ®Google Scholar
• Faucette SR, Hawke RL, Lecluyse EL et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab. Dispos.28(10), 1222–1230 (2000).
   PubMed Web of Science ®Google Scholar
• Hesse LM, Venkatakrishnan K, Court MH et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab. Dispos.28(10), 1176–1183 (2000).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Klein C, Meineke I et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics13(10), 619–626 (2003).
   PubMedGoogle Scholar
• Faucette SR, Hawke RL, Shord SS, et al. Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation. Drug Metab. Dispos.29(8), 1123–1129 (2001).
   PubMed Web of Science ®Google Scholar
• Kotlyar M, Brauer LH, Tracy TS et al. Inhibition of CYP2D6 activity by bupropion. J. Clin. Psychopharmacol.25(3), 226–229 (2005).
   PubMed Web of Science ®Google Scholar
• Weintraub D. Nortriptyline toxicity secondary to interaction with bupropion sustained-release. Depress. Anxiety13(1), 50–52 (2001).
   PubMed Web of Science ®Google Scholar
• Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J. Affect. Disord.51(3), 237–254 (1998).
   PubMed Web of Science ®Google Scholar
• Ascher JA, Cole JO, Colin JN et al. Bupropion: a review of its mechanism of antidepressant activity. J. Clin. Psychiatry56(9), 395–401 (1995).
   PubMed Web of Science ®Google Scholar
• Stahl SM, Pradko JF, Haight BR et al. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim. Care Companion J. Clin. Psychiatry6(4), 159–166 (2004).
   PubMedGoogle Scholar
• Nomikos GG, Damsma G, Wenkstern D, et al. Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum. Neuropsychopharmacology7(1), 7–14 (1992).
   PubMed Web of Science ®Google Scholar
• Richelson E. Synaptic effects of antidepressants. J. Clin. Psychopharmacol.16(3 Suppl. 2), 1S–7S; discussion 7S (1996).
   PubMedGoogle Scholar
• Kavoussi RJ, Segraves RT, Hughes AR, et al. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J. Clin. Psychiatry58(12), 532–537 (1997).
   PubMed Web of Science ®Google Scholar
• Croft H, Settle E, Jr., Houser T et al. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin. Ther.21(4), 643–658 (1999).
   PubMed Web of Science ®Google Scholar
• Coleman CC, Cunningham LA, Foster VJ et al. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann. Clin. Psychiatry11(4), 205–215 (1999).
   PubMedGoogle Scholar
• Weihs KL, Settle EC, Jr., Batey SR et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J. Clin. Psychiatry61(3), 196–202 (2000).
   PubMed Web of Science ®Google Scholar
• Clayton AH, Croft HA, Horrigan JP et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J. Clin. Psychiatry67(5), 736–746 (2006).
   PubMed Web of Science ®Google Scholar
• Feighner JP, Gardner EA, Johnston JA et al. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J. Clin. Psychiatry52(8), 329–335 (1991).
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. A multicenter, double-blind, placebo-controlled comparison of the safety and efficacy and effects on sexual functioning of wellbutrin (bupropion hcl) sustained release (SR) and fluoxetine in outpatients with moderate to severe recurrent major depression. AK1A4006. Accessed March 13 2007 (Data on file).
   Google Scholar
• Coleman CC, King BR, Bolden-Watson C et al. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin. Ther.23(7), 1040–1058 (2001).
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Fulton KA, Bagby RM et al. Sexual function during bupropion or paroxetine treatment of major depressive disorder. Can. J. Psychiatry51(4), 234–242 (2006).
   PubMed Web of Science ®Google Scholar
• Jamerson BD, Krishnan KR, Roberts J, et al. Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression. Psychopharmacol. Bull.37(2), 67–78 (2003).
   PubMedGoogle Scholar
• GlaxoSmithKline. A multicenter, double-blind, placebo-controlled comparison of the efficacy and safety of flexible dose extended-release bupropion hydrochloride (HCl) 300–450 mg/day and placebo administered for eight weeks for the treatment of adult outpatients with major depressive disorder including symptoms of decreased energy, pleasure, and interest. AK130931. Accessed March 13 2007 (Data on file).
   Google Scholar
• Green TR. Bupropion for SSRI-induced fatigue. J. Clin. Psychiatry58(4), 174 (1997).
   PubMedGoogle Scholar
• Craig T, Kakumanu S. Chronic fatigue syndrome: evaluation and treatment. Am. Fam. Physician65(6), 1083–1090 (2002).
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Prescribing information of bupropion XL.
   Google Scholar
• Baldwin DS, Papakostas GI. Symptoms of fatigue and sleepiness in major depressive disorder. J. Clin. Psychiatry67(Suppl. 6), 9–15 (2006).
   PubMed Web of Science ®Google Scholar
• Davis MP, Khoshknabi D, Yue GH. Management of fatigue in cancer patients. Curr. Pain Headache Rep.10(4), 260–269 (2006).
   PubMedGoogle Scholar
• Kollins SH, MacDonald EK, Rush CR. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol. Biochem. Behav.68(3), 611–627 (2001).
   PubMed Web of Science ®Google Scholar
• DeBattista C, Doghramji K, Menza MA et al. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J. Clin. Psychiatry64(9), 1057–1064 (2003).
   PubMed Web of Science ®Google Scholar
• Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J. Clin. Psychiatry66(1), 85–93 (2005).
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Petersen TJ, Burns AM et al. Adjunctive atomoxetine for residual fatigue in major depressive disorder. J. Psychiatr. Res.40(4), 370–373 (2006).
   PubMed Web of Science ®Google Scholar
• Foley KF, DeSanty KP, Kast RE. Bupropion: pharmacology and therapeutic applications. Expert Rev. Neurother.6(9), 1249–1265 (2006).
   PubMed Web of Science ®Google Scholar
• Gadde KM, Xiong GL. Bupropion for weight reduction. Expert Rev. Neurother.7(1), 17–24 (2007).
   PubMedGoogle Scholar
• Gartlehner G, Hansen RA, Carey TS et al. Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis. Int. Clin. Psychopharmacol.20(2), 59–69 (2005).
   PubMed Web of Science ®Google Scholar